How has Pfizer's disitamab vedotin — intangible asset impairments changed year-over-year?

Pfizer's disitamab vedotin — intangible asset impairments increased by 700.0% year-over-year, from $50.00M to $400.00M.

Products & Services · Intangible asset impairments

disitamab vedotin — Intangible asset impairments

Pfizer disitamab vedotin — Intangible asset impairments remained flat by 0.0% to $400.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 700.0%, from $50.00M to $400.00M.

Analysis

StatementSegment

First reportedQ1 2024

Last reportedQ4 2025Feb 26, 2026

Rolls up toImpairment Charges

Metric ID: pfe_segment_disitamab_vedotin_intangible_asset_impairments

Historical Data

2 years

	FY'24	FY'25
Value	$200.00M	$1.60B
YoY Change	—	+700.0%

Range$200.00M – $1.60B

Avg YoY Growth+700.0%

Median YoY Growth+700.0%

Frequently Asked Questions

What is Pfizer's disitamab vedotin — intangible asset impairments?: Pfizer (PFE) reported disitamab vedotin — intangible asset impairments of $400.00M in Q4 2025.
How has Pfizer's disitamab vedotin — intangible asset impairments changed year-over-year?: Pfizer's disitamab vedotin — intangible asset impairments increased by 700.0% year-over-year, from $50.00M to $400.00M.